The role of AGEs and ROS in atherosclerosis;Die Bedeutung von AGEs und ROS bei Atherosklerose

Herz

Volumn 35, Issue 3, 2010, Pages 170-180

  Stirban, Alin ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Advanced glycation end products (AGEs); Atherosclerosis; Endothelial dysfunction; Oxidative stress; Reactive oxygen species (ROS)

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BENFOTIAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN; METFORMIN; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROSCLEROSIS; ENDOTHELIAL DYSFUNCTION; INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; REVIEW;

EID: 77952823016     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-010-3338-y     Document Type: Review

References (122)

1. S.M. Grundy J.I. Cleeman C.N. Merz 2004 Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 227 39 15249516 10.1161/01.CIR.0000133317.49796.0E (Pubitemid 38924592)
2. J. Stamler O. Vaccaro J.D. Neaton 1993 Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial Diabetes Care 16 434 44 8432214 10.2337/diacare.16.2.434 1:STN:280:DyaK3s7mtFyrtQ%3D%3D
3. G. Panzram 1987 Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus Diabetologia 30 123 31 3556287 10.1007/BF00274216 1:STN:280:DyaL2s3hvFGqsg%3D%3D (Pubitemid 17056996)
4. S.M. Haffner S. Lehto T. Ronnemaa 1998 Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 229 34 9673301 10.1056/NEJM199807233390404 1:STN:280:DyaK1czivVKgsg%3D%3D (Pubitemid 28350165)
5. R. Ross 1993 The pathogenesis of atherosclerosis: a perspective for the 1990s Nature 362 801 9 8479518 10.1038/362801a0 1:CAS:528:DyaK3sXktVGqu7c%3D (Pubitemid 23132154)
6. H. Kawano T. Motoyama O. Hirashima 1999 Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery J Am Coll Cardiol 34 146 54 10400004 10.1016/S0735-1097(99)00168-0 1:STN:280: DyaK1MzisFGqsw%3D%3D
7. S. Taddei L. Ghiadoni A. Virdis 2003 Mechanisms of endothelial dysfunction: clinical significance and preventive non-pharmacological therapeutic strategies Curr Pharm Des 9 2385 402 14529554 10.2174/ 1381612033453866 1:CAS:528:DC%2BD3sXotlWjtrY%3D (Pubitemid 37236360)
8. A. Ceriello C. Taboga L. Tonutti 2002 Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment Circulation 106 1211 8 12208795 10.1161/01.CIR.0000027569.76671.A8 (Pubitemid 34988638)
9. M. Brownlee 2005 The pathobiology of diabetic complications: a unifying mechanism Diabetes 54 1615 25 15919781 10.2337/diabetes.54.6.1615 1:CAS:528:DC%2BD2MXltVaisbk%3D (Pubitemid 40770750)
10. A.G. Huebschmann J.G. Regensteiner H. Vlassara 2006 Diabetes and advanced glycoxidation end products Diabetes Care 29 1420 32 16732039 10.2337/dc05-2096 1:CAS:528:DC%2BD28XmtFKls7o%3D (Pubitemid 44125953)
11. N. Ahmed 2005 Advanced glycation endproducts - role in pathology of diabetic complications Diabetes Res Clin Pract 67 3 21 15620429 10.1016/j.diabres.2004.09.004 1:CAS:528:DC%2BD2cXhtFGhsb7I (Pubitemid 40037725)
12. S. Schiekofer M. Andrassy J. Chen 2003 Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs Diabetes 52 621 33 12606501 10.2337/diabetes.52.3.621 1:CAS:528:DC%2BD3sXitFajsbo%3D (Pubitemid 36323567)
13. H. Vlassara R. Bucala 1996 Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors Diabetes 45 Suppl3 S65 6 8674896 1:CAS:528:DyaK28XjvFartbs%3D
14. I. Giardino D. Edelstein M. Brownlee 1994 Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes J Clin Invest 94 110 7 8040253 10.1172/JCI117296 1:CAS:528:DyaK2cXltlWnt7g%3D
15. A. J. Furth 1997 Glycated proteins in diabetes Br J Biomed Sci 54 192 200 9499597 1:CAS:528:DyaK2sXmsF2htLY%3D
16. D.R. McCance D.G. Dyer J.A. Dunn 1993 Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus J Clin Invest 91 2470 8 8514859 10.1172/JCI116482 1:CAS:528:DyaK3sXltlKkt7k%3D
17. A. Bierhaus M.A. Hofmann R. Ziegler 1998 AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept Cardiovasc Res 37 586 600 9659442 10.1016/S0008-6363(97)00233-2 1:CAS:528:DyaK1cXivVKms78%3D (Pubitemid 28231153)
18. T. Miyata K. Kurokawa C. van Ypersele de Strihou 2000 Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism J Am Soc Nephrol 11 1744 52 10966500 1:CAS:528:DC%2BD3cXntFKru7c%3D
19. T. Goldberg W. Cai M. Peppa 2004 Advanced glycoxidation end products in commonly consumed foods J Am Diet Assoc 104 1287 91 15281050 10.1016/j.jada.2004.05.214 1:CAS:528:DC%2BD2cXntV2ktL4%3D (Pubitemid 39036519)
20. A.C. McLellan P.J. Thornalley J. Benn 1994 Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications Clin Sci (Lond) 87 21 9 1:STN:280:DyaK2czktVyrtQ%3D%3D
21. A.S. Charonis L.A. Reger J.E. Dege 1990 Laminin alterations after in vitro nonenzymatic glycosylation Diabetes 39 807 14 2113013 10.2337/diabetes.39. 7.807 1:CAS:528:DyaK3MXkt1Ki
22. H. Vlassara W. Cai J. Crandall 2002 Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy Proc Natl Acad Sci U S A 99 15596 601 12429856 10.1073/pnas.242407999 1:CAS:528:DC%2BD3sXjvVyr (Pubitemid 35403978)
23. H. Vlassara 1996 Advanced glycation end-products and atherosclerosis Ann Med 28 419 26 8949973 10.3109/07853899608999102 1:STN:280:DyaK2s7gslahtw%3D%3D
24. J.W. Baynes 1991 Role of oxidative stress in development of complications in diabetes Diabetes 40 405 12 2010041 10.2337/diabetes.40.4.405 1:CAS:528:DyaK3MXktVGqur8%3D
25. H. Vlassara M.R. Palace 2002 Diabetes and advanced glycation endproducts J Intern Med 251 87 101 11905595 10.1046/j.1365-2796.2002.00932.x 1:CAS:528:DC%2BD38XitVChsro%3D (Pubitemid 34146691)
26. V.M. Monnier G.T. Mustata K.L. Biemel 2005 Cross-linking of the extracellular matrix by the Maillard reaction in aging and diabetes: an update on "a puzzle nearing resolution" Ann N Y Acad Sci 1043 533 44 16037276 10.1196/annals.1333.061 1:CAS:528:DC%2BD2MXpvVKqtLg%3D (Pubitemid 41123943)
27. R. Singh A. Barden T. Mori 2001 Advanced glycation end-products: a review Diabetologia 44 129 46 11270668 10.1007/s001250051591 1:CAS:528: DC%2BD3MXntlSltg%3D%3D (Pubitemid 32156196)
28. R. Bucala Z. Makita T. Koschinsky 1993 Lipid advanced glycosylation: pathway for lipid oxidation in vivo Proc Natl Acad Sci U S A 90 6434 8 8341651 10.1073/pnas.90.14.6434 1:CAS:528:DyaK3sXlsFOltrs%3D
29. H. Vlassara 2001 The AGE-receptor in the pathogenesis of diabetic complications Diabetes Metab Res Rev 17 436 43 11757079 10.1002/dmrr.233 1:CAS:528:DC%2BD38XnsFSktg%3D%3D (Pubitemid 34030746)
30. A. Bierhaus P.M. Humpert M. Morcos 2005 Understanding RAGE, the receptor for advanced glycation end products J Mol Med 83 876 86 16133426 10.1007/s00109-005-0688-7 1:CAS:528:DC%2BD2MXht1SksbjP (Pubitemid 41598688)
31. Z. Zhou D. Immel C.X. Xi 2006 Regulation of osteoclast function and bone mass by RAGE J Exp Med 203 1067 80 16606672 10.1084/jem.20051947 1:CAS:528:DC%2BD28Xjsl2isLk%3D
32. C. Lu J.C. He W. Cai 2004 Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells Proc Natl Acad Sci U S A 101 11767 72 15289604 10.1073/pnas.0401588101 1:CAS:528:DC%2BD2cXntVersrg%3D (Pubitemid 39099304)
33. G. Pugliese F. Pricci C. Iacobini 2001 Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice FASEB J 15 2471 9 11689472 10.1096/fj.01-0006com 1:CAS:528:DC%2BD3MXoslSitL0%3D (Pubitemid 33063175)
34. J.J. Li D. Dickson P.R. Hof 1998 Receptors for advanced glycosylation endproducts in human brain: role in brain homeostasis Mol Med 4 46 60 9513189 1:CAS:528:DyaK1cXhslWjtb8%3D
35. H. Vlassara 1997 Recent progress in advanced glycation end products and diabetic complications Diabetes 46 Suppl2 S19 25 9285494 1:CAS:528: DyaK2sXlvFKgtbs%3D
36. A.W. Stitt C. He H. Vlassara 1999 Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells Biochem Biophys Res Commun 256 549 56 10080935 10.1006/bbrc.1999.0291 1:CAS:528:DyaK1MXhvVaht7c%3D (Pubitemid 29301143)
37. G.K. Reddy 2004 Cross-linking in collagen by nonenzymatic glycation increases the matrix stiffness in rabbit achilles tendon Exp Diabesity Res 5 143 53 15203885 10.1080/15438600490277860 1:CAS:528:DC%2BD2cXnt1Gksbg%3D (Pubitemid 38868239)
38. S. McFarlane J.V. Glenn A.M. Lichanska 2005 Characterisation of the advanced glycation endproduct receptor complex in the retinal pigment epithelium Br J Ophthalmol 89 107 12 15615757 10.1136/bjo.2004.045914 1:STN:280: DC%2BD2M%2FhslyitA%3D%3D (Pubitemid 40040249)
39. L.G. Bucciarelli T. Wendt L. Rong 2002 RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease Cell Mol Life Sci 59 1117 28 12222959 10.1007/s00018-002-8491-x 1:CAS:528:DC%2BD38Xmtlersr4%3D
40. R. Ramasamy S.J. Vannucci S.S. Yan 2005 Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation Glycobiology 15 16R 28R 15764591 10.1093/glycob/cwi053 1:CAS:528:DC%2BD2MXlvFSrtrk%3D (Pubitemid 41417992)
41. P. Rosen P.P. Nawroth G. King 2001 The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a congress series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society Diabetes Metab Res Rev 17 189 212 11424232 10.1002/dmrr.196 1:CAS:528:DC%2BD3MXlslOhurs%3D (Pubitemid 32624602)
42. A. Neumann R. Schinzel D. Palm 1999 High molecular weight hyaluronic acid inhibits advanced glycation end-product-induced NF-kappaB activation and cytokine expression FEBS Lett 453 283 7 10405161 10.1016/S0014-5793(99)00731-0 1:CAS:528:DyaK1MXkt1ahu7Y%3D (Pubitemid 29326664)
43. S.D. Yan A.M. Schmidt G.M. Anderson 1994 Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins J Biol Chem 269 9889 97 8144582 1:CAS:528: DyaK2cXis1Ogsrg%3D
44. R.M. Wever T.F. Luscher F. Cosentino 1998 Atherosclerosis and the two faces of endothelial nitric oxide synthase Circulation 97 108 12 9443438 1:CAS:528:DyaK1cXlvVeitw%3D%3D
45. J.M. Griscavage S. Wilk L.J. Ignarro 1996 Inhibitors of the proteasome pathway interfere with induction of nitric oxide synthase in macrophages by blocking activation of transcription factor NF-kappa B Proc Natl Acad Sci U S A 93 3308 12 8622934 10.1073/pnas.93.8.3308 1:CAS:528:DyaK28XisVWisLs%3D (Pubitemid 26125615)
46. A.K. Mohamed A. Bierhaus S. Schiekofer 1999 The role of oxidative stress and NF-kappaB activation in late diabetic complications Biofactors 10 157 67 10609877 10.1002/biof.5520100211 1:CAS:528:DyaK1MXotVKjsr8%3D
47. R.A. Kowluru 2005 Effect of advanced glycation end products on accelerated apoptosis of retinal capillary cells under in vitro conditions Life Sci 76 1051 60 15607333 10.1016/j.lfs.2004.10.017 1:CAS:528:DC%2BD2cXhtVyqsbzJ (Pubitemid 39643404)
48. F. Cipollone A. Iezzi M. Fazia 2003 The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control Circulation 108 1070 7 12912808 10.1161/01.CIR.0000086014.80477.0D 1:CAS:528:DC%2BD3sXms1altbs%3D (Pubitemid 37071516)
49. D.M. Stern S.D. Yan S.F. Yan 2002 Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes Ageing Res Rev 1 1 15 12039445 10.1016/S0047-6374(01)00366-9 1:CAS:528:DC%2BD38XosVejsrY%3D (Pubitemid 38340348)
50. C.J. He T. Koschinsky C. Buenting 2001 Presence of diabetic complications in type 1 diabetic patients correlates with low expression of mononuclear cell AGE-receptor-1 and elevated serum AGE Mol Med 7 159 68 11471552 1:CAS:528:DC%2BD3MXjtFWntro%3D
51. W. Cai J.C. He L. Zhu 2006 Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor Proc Natl Acad Sci U S A 103 13801 6 16954185 10.1073/pnas.0600362103 1:CAS:528:DC%2BD28XpvFSltbY%3D (Pubitemid 44413988)
52. H. Vlassara J. Uribarri 2004 Glycoxidation and diabetic complications: modern lessons and a warning? Rev Endocr Metab Disord 5 181 8 15211089 10.1023/B:REMD.0000032406.84813.f6 1:CAS:528:DC%2BD2cXltVWrsbs%3D (Pubitemid 38903575)
53. A. Rojas M.A. Morales 2004 Advanced glycation and endothelial functions: a link towards vascular complications in diabetes Life Sci 76 715 30 15581904 10.1016/j.lfs.2004.09.011 1:CAS:528:DC%2BD2cXhtVCltb7M (Pubitemid 39576147)
54. G. Basta G. Lazzerini M. Massaro 2002 Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses Circulation 105 816 22 11854121 10.1161/hc0702.104183 1:CAS:528:DC%2BD38XitlOls7g%3D (Pubitemid 34174921)
55. A.M. Schmidt S.D. Yan J.L. Wautier 1999 Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis Circ Res 84 489 97 10082470 1:CAS:528:DyaK1MXitVSku7k%3D
56. S. Yamagishi H. Fujimori H. Yonekura 1998 Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells Diabetologia 41 1435 41 9867210 10.1007/s001250051089 1:CAS:528:DyaK1cXnvVaiurk%3D (Pubitemid 28551614)
57. T. Gawlowski B. Stratmann A.O. Stirban 2007 AGEs and methylglyoxal induce apoptosis and expression of Mac-1 on neutrophils resulting in platelet-neutrophil aggregation Thromb Res 121 117 26 17445870 10.1016/j.thromres.2007.03.002 1:CAS:528:DC%2BD2sXht1KrsbzI (Pubitemid 350025999)
58. T. Gawlowski B. Stratmann R. Ruetter 2009 Advanced glycation end products strongly activate platelets Eur J Nutr 48 475 81 19633966 10.1007/s00394-009- 0038-6 1:CAS:528:DC%2BD1MXhtlant7bE
59. C. Cerami H. Founds I. Nicholl 1997 Tobacco smoke is a source of toxic reactive glycation products Proc Natl Acad Sci U S A 94 13915 20 9391127 10.1073/pnas.94.25.13915 1:CAS:528:DyaK2sXotVeiu7k%3D (Pubitemid 28009684)
60. H. Vlassara 2005 Advanced glycation in health and disease: role of the modern environment Ann N Y Acad Sci 1043 452 60 16037266 10.1196/annals.1333.051 1:CAS:528:DC%2BD2MXpvVKqt7g%3D (Pubitemid 41123933)
61. T. Koschinsky C.J. He T. Mitsuhashi 1997 Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy Proc Natl Acad Sci U S A 94 6474 9 9177242 10.1073/pnas.94.12.6474 1:CAS:528:DyaK2sXjvFGhu7g%3D (Pubitemid 27270709)
62. A. Forster Y. Kuhne T. Henle 2005 Studies on absorption and elimination of dietary Maillard reaction products Ann N Y Acad Sci 1043 474 81 16037269 10.1196/annals.1333.054 1:CAS:528:DC%2BD2MXpvVKqt7c%3D (Pubitemid 41123936)
63. P.J. Beisswenger S.K. Howell R.M. O'Dell 2001 Alpha-dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia Diabetes Care 24 726 32 11315838 10.2337/diacare.24.4.726 1:CAS:528:DC%2BD3MXivVOmurs%3D
64. Z. Makita S. Radoff E.J. Rayfield 1991 Advanced glycosylation end products in patients with diabetic nephropathy N Engl J Med 325 836 42 1875967 1:STN:280:DyaK3Mzkt1OisQ%3D%3D
65. H. Vlassara M.R. Palace 2003 Glycoxidation: the menace of diabetes and aging Mt Sinai J Med 70 232 41 12968196
66. N. Turk A. Mornar V. Mrzljak 2004 Urinary excretion of advanced glycation endproducts in patients with type 2 diabetes and various stages of proteinuria Diabetes Metab 30 187 92 15223992 10.1016/S1262-3636(07)70106-4 1:CAS:528:DC%2BD2cXltlKhtL4%3D
67. B. Smedsrod J. Melkko N. Araki 1997 Advanced glycation end products are eliminated by scavenger-receptor-mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells Biochem J 322 567 73 9065778 1:CAS:528: DyaK2sXhvFarsro%3D
68. H. Sano T. Higashi K. Matsumoto 1998 Insulin enhances macrophage scavenger receptor-mediated endocytic uptake of advanced glycation end products J Biol Chem 273 8630 7 9535837 10.1074/jbc.273.15.8630 1:CAS:528: DyaK1cXis1elsbw%3D (Pubitemid 28176138)
69. H. Sano R. Nagai K. Matsumoto 1999 Receptors for proteins modified by advanced glycation endproducts (AGE) - their functional role in atherosclerosis Mech Ageing Dev 107 333 46 10360686 10.1016/S0047-6374(99)00011-1 1:CAS:528:DyaK1MXit1WqsLg%3D (Pubitemid 29210233)
70. A.W. Stitt C. He S. Friedman 1997 Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs Mol Med 3 617 27 9323713 1:CAS:528:DyaK2sXntFCitrk%3D
71. T. Niwa T. Katsuzaki S. Miyazaki 1997 Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients J Clin Invest 99 1272 80 9077536 10.1172/JCI119285 1:CAS:528:DyaK2sXhvFyhs7c%3D
72. M.F. Lopes-Virella R.L. Klein T.J. Lyons 1988 Glycosylation of low-density lipoprotein enhances cholesteryl ester synthesis in human monocyte-derived macrophages Diabetes 37 550 7 3129328 10.2337/diabetes.37.5.550 1:CAS:528:DyaL1cXktVGis7g%3D
73. J.L. Goldstein Y.K. Ho S.K. Basu 1979 Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition Proc Natl Acad Sci U S A 76 333 7 218198 10.1073/pnas.76.1.333 1:CAS:528:DyaE1MXhtFylu7g%3D
74. R. Bucala Z. Makita G. Vega 1994 Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency Proc Natl Acad Sci U S A 91 9441 5 7937786 10.1073/pnas.91.20.9441 1:CAS:528:DyaK2cXmt1Ort7Y%3D
75. P.B. Duell J.F. Oram E.L. Bierman 1991 Nonenzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux Diabetes 40 377 84 1847886 10.2337/diabetes.40.3.377 1:CAS:528:DyaK3MXhsVSguro%3D
76. M. Brownlee H. Vlassara A. Cerami 1985 Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein Diabetes 34 938 41 4029512 10.2337/diabetes.34.9.938 1:CAS:528:DyaL2MXltl2ksro%3D
77. J. Zhang S. Ren G.X. Shen 2000 Glycation amplifies lipoprotein(a)-induced alterations in the generation of fibrinolytic regulators from human vascular endothelial cells Atherosclerosis 150 299 308 10856522 10.1016/S0021-9150(99) 00381-0 1:CAS:528:DC%2BD3cXktVSnu7k%3D (Pubitemid 30336542)
78. R. Bucala K.J. Tracey A. Cerami 1991 Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes J Clin Invest 87 432 8 1991829 10.1172/JCI115014 1:CAS:528:DyaK3MXhtF2lsLc%3D
79. X. Wang K. Desai T. Chang 2005 Vascular methylglyoxal metabolism and the development of hypertension J Hypertens 23 1565 73 16003184 10.1097/01.hjh. 0000173778.85233.1b 1:CAS:528:DC%2BD2MXlvVymtLg%3D
80. L. Rodriguez-Manas J. Angulo S. Vallejo 2003 Early and intermediate Amadori glycosylation adducts, oxidative stress, and endothelial dysfunction in the streptozotocin-induced diabetic rats vasculature Diabetologia 46 556 66 12739028 1:CAS:528:DC%2BD3sXjsFejs70%3D
81. A. Ceriello E. Motz 2004 Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited Arterioscler Thromb Vasc Biol 24 816 23 14976002 10.1161/01.ATV.0000122852.22604.78 1:CAS:528:DC%2BD2cXjsFSntLo%3D (Pubitemid 38620857)
82. B. Guerci P. Bohme A. Kearney-Schwartz 2001 Endothelial dysfunction and type 2 diabetes. Part 2: Altered endothelial function and the effects of treatments in type 2 diabetes mellitus Diabetes Metab 27 436 47 11547217 1:CAS:528:DC%2BD3MXovVOqsL8%3D
83. A. Bast G. Wolf I. Oberbaumer 2002 Oxidative and nitrosative stress induces peroxiredoxins in pancreatic beta cells Diabetologia 45 867 76 12107731 10.1007/s00125-002-0846-1 1:CAS:528:DC%2BD38XkslSnsr8%3D
84. A. Ceriello 2002 Nitrotyrosine: new findings as a marker of post-prandial oxidative stress Int J Clin Pract Suppl 129 51 8 12166608 1:CAS:528: DC%2BD38XmsVKksbY%3D
85. N.K. Gopaul E.E. Anggard A.I. Mallet 1995 Plasma 8-epi-PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus FEBS Lett 368 225 9 7628610 10.1016/0014-5793(95)00649-T 1:CAS:528:DyaK2MXntFCkurc%3D
86. E. Altomare G. Vendemiale D. Chicco 1992 Increased lipid peroxidation in type 2 poorly controlled diabetic patients Diabete Metab 18 264 71 1459313 1:CAS:528:DyaK3sXkvFaqsL8%3D
87. D. Giugliano A. Ceriello G. Paolisso 1996 Oxidative stress and diabetic vascular complications Diabetes Care 19 257 67 8742574 10.2337/diacare.19.3.257 1:STN:280:DyaK28zktF2muw%3D%3D
88. T. Heitzer T. Schlinzig K. Krohn 2001 Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease Circulation 104 2673 8 11723017 10.1161/hc4601.099485 1:CAS:528:DC%2BD38Xht1CitQ%3D%3D
89. K.H. Gabbay L.O. Merola R.A. Field 1966 Sorbitol pathway: presence in nerve and cord with substrate accumulation in diabetes Science 151 209 10 5907911 10.1126/science.151.3707.209 1:CAS:528:DyaF28XntVarug%3D%3D
90. A. Ceriello 2003 New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy Diabetes Care 26 1589 96 12716823 10.2337/diacare.26.5.1589 1:CAS:528:DC%2BD3sXjvVegsbk%3D (Pubitemid 36929196)
91. A.Y. Lee S.S. Chung 1999 Contributions of polyol pathway to oxidative stress in diabetic cataract FASEB J 13 23 30 9872926 1:CAS:528: DyaK1MXlt1ygtg%3D%3D
92. K. Sebekova K. Gazdikova D. Syrova 2003 Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products J Hum Hypertens 17 265 70 12692571 10.1038/sj.jhh.1001541 1:CAS:528:DC%2BD3sXivVWku7s%3D (Pubitemid 36592018)
93. D.M. Nathan J. Lachin P. Cleary 2003 Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus N Engl J Med 348 2294 303 12788993 10.1056/NEJMoa022314 (Pubitemid 36638103)
94. D.M. Nathan P.A. Cleary J.Y. Backlund 2005 Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes N Engl J Med 353 2643 53 16371630 10.1056/NEJMoa052187 (Pubitemid 41817713)
95. S. Yamagishi T. Imaizumi 2005 Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy Curr Pharm Des 11 2279 99 16022668 10.2174/1381612054367300 1:CAS:528:DC%2BD2MXlsV2gtL0%3D (Pubitemid 40872698)
96. O. Sandu K. Song W. Cai 2005 Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake Diabetes 54 2314 9 16046296 10.2337/diabetes.54.8.2314 1:CAS:528:DC%2BD2MXnt1ynsbY%3D (Pubitemid 41134257)
97. R.Y. Lin E.D. Reis A.T. Dore 2002 Lowering of dietary advanced glycation endproducts (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice Atherosclerosis 163 303 11 12052477 10.1016/S0021-9150(02)00008-4 1:CAS:528:DC%2BD38XktFOnsbg%3D (Pubitemid 34615821)
98. R.Y. Lin R.P. Choudhury W. Cai 2003 Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice Atherosclerosis 168 213 20 12801603 10.1016/S0021-9150(03)00050-9 1:CAS:528:DC%2BD3sXksVOktbY%3D (Pubitemid 36703319)
99. M. Peppa H. Brem P. Ehrlich 2003 Adverse effects of dietary glycotoxins on wound healing in genetically diabetic mice Diabetes 52 2805 13 14578300 10.2337/diabetes.52.11.2805 1:CAS:528:DC%2BD3sXovVagtLo%3D (Pubitemid 37339711)
100. F. Zheng C. He W. Cai 2002 Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products Diabetes Metab Res Rev 18 224 37 12112941 10.1002/dmrr.283 (Pubitemid 34778386)
101. S.M. Hofmann H.J. Dong Z. Li 2002 Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse Diabetes 51 2082 9 12086936 10.2337/diabetes.51.7.2082 1:CAS:528:DC%2BD38Xlt1Wlt7w%3D
102. J.M. Forbes L.T. Yee V. Thallas 2004 Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis Diabetes 53 1813 23 15220206 10.2337/diabetes.53.7.1813 1:CAS:528:DC%2BD2cXlslWgtLg%3D (Pubitemid 38857040)
103. J. Berlanga D. Cibrian I. Guillen 2005 Methylglyoxal administration induces diabetes-like microvascular changes and perturbs the healing process of cutaneous wounds Clin Sci (Lond) 109 83 95 10.1042/CS20050026 1:CAS:528:DC%2BD2MXntlSnu7c%3D (Pubitemid 40943037)
104. R. Tamarat J.S. Silvestre M. Huijberts 2003 Blockade of advanced glycation end-product formation restores ischemia-induced angiogenesis in diabetic mice Proc Natl Acad Sci U S A 100 8555 60 12805564 10.1073/pnas. 1236929100 1:CAS:528:DC%2BD3sXlsFGnurc%3D (Pubitemid 36842582)
105. N. Ahmed P.J. Thornalley 2007 Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab 9 233 45 17391149 10.1111/j.1463-1326.2006.00595.x 1:CAS:528:DC%2BD2sXlvVSlu7s%3D (Pubitemid 46502041)
106. M. Negrean A. Stirban T. Horstmann 2005 Food advanced glycation endproducts (AGE) acutely induce vascular dysfunction in patients with type 2 diabetes mellitus, an effect reduced by benfotiamine Diabetologia 48 Suppl1 A415
107. P. Pouillart H. Mauprivez L. Ait-Ameur 2008 Strategy for the study of the health impact of dietary Maillard products in clinical studies: the example of the ICARE clinical study on healthy adults Ann N Y Acad Sci 1126 173 6 18448812 10.1196/annals.1433.040 1:CAS:528:DC%2BD1cXmtFygu7g%3D (Pubitemid 351589302)
108. J. Uribarri M. Peppa W. Cai 2003 Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients Am J Kidney Dis 42 532 8 12955681 10.1016/S0272-6386(03)00779-0 1:CAS:528: DC%2BD3sXnsleisb8%3D (Pubitemid 37048129)
109. J. Uribarri W. Cai O. Sandu 2005 Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects Ann N Y Acad Sci 1043 461 6 16037267 10.1196/annals.1333.052 1:CAS:528:DC%2BD2MXpvVKqt7k%3D (Pubitemid 41123934)
110. N. Ahmed R. Babaei-Jadidi S.K. Howell 2005 Glycated and oxidized protein degradation products are indicators of fasting and postprandial hyperglycemia in diabetes Diabetes Care 28 2465 71 16186281 10.2337/diacare.28.10.2465 1:CAS:528:DC%2BD2MXhtFGqtr3F (Pubitemid 41384295)
111. J. Uribarri M. Peppa W. Cai 2003 Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients J Am Soc Nephrol 14 728 31 12595509 10.1097/01.ASN.0000051593.41395.B9 1:CAS:528:DC%2BD3sXht1KjtrY%3D (Pubitemid 36246017)
112. W. Cai J.C. He L. Zhu 2004 High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients Circulation 110 285 91 15249511 10.1161/01.CIR.0000135587.92455.0D 1:CAS:528: DC%2BD2cXlsFyjtb8%3D (Pubitemid 38955497)
113. A. Stirban M. Negrean B. Stratmann 2006 Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes Diabetes Care 29 2064 71 16936154 10.2337/dc06-0531 1:CAS:528:DC%2BD28XhtVegsrnP (Pubitemid 44871188)
114. A. Stirban M. Negrean B. Stratmann 2007 Adiponectin decreases postprandially following a heat-processed meal in individuals with type 2 diabetes: an effect prevented by benfotiamine and cooking method Diabetes Care 30 2514 6 17630265 10.2337/dc07-0302 (Pubitemid 47547785)
115. A. Stirban M. Negrean C. Götting 2008 Leptin decreases postprandially in people with type 2 diabetes - an effect reduced by the cooking method Horm Metab Res 40 896 900 18792885 10.1055/s-0028-1083784 1:CAS:528:DC%2BD1MXhsleht7s%3D
116. J. Uribarri A. Stirban D. Sander 2007 Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects Diabetes Care 30 2579 82 17496238 10.2337/dc07-0320 1:CAS:528:DC%2BD2sXht1CltrnM (Pubitemid 47547799)
117. Y. Tanaka H. Uchino T. Shimizu 1999 Effect of metformin on advanced glycation endproduct formation and peripheral nerve function in streptozotocin-induced diabetic rats Eur J Pharmacol 376 17 22 10440084 10.1016/S0014-2999(99)00342-8 1:CAS:528:DyaK1MXks1Crsb4%3D (Pubitemid 29320165)
118. K. Nakamura S. Yamagishi Y. Nakamura 2005 Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension Microvasc Res 70 137 41 16271939 10.1016/j.mvr.2005.10.002 1:CAS:528:DC%2BD2MXhtFOmtLrM (Pubitemid 41586467)
119. H.P. Hammes X. Du D. Edelstein 2003 Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy Nat Med 9 294 9 12592403 10.1038/nm834 1:CAS:528:DC%2BD3sXhsFGgsLo%3D (Pubitemid 36362784)
120. T. Miyata Y. Iida K. Horie 1996 Pathophysiology of advanced glycation end-products in renal failure Nephrol Dial Transplant 11 Suppl5 27 30 9044303 1:CAS:528:DyaK2sXhsFCitb4%3D (Pubitemid 27062907)
121. K.C. Tan W.S. Chow J.C. Lam 2006 Advanced glycation endproducts in nondiabetic patients with obstructive sleep apnea Sleep 29 329 33 16553018
122. M. Friedman 2005 Biological effects of Maillard browning products that may affect acrylamide safety in food: biological effects of Maillard products Adv Exp Med Biol 561 135 56 16438296 10.1007/0-387-24980-X-12 1:CAS:528:DC%2BD2MXhtVWgurjE (Pubitemid 43785879)